Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Sep 15;62(Suppl 1):S53–S66. doi: 10.1002/jcph.2129

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 The Authors. The Journal of Clinical Pharmacology published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.

This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

PMC Copyright notice

Fetal SVT. (a) Heart rate trend over 5 minutes. In this case, the fetus is in SVT at about 194/min for nearly the entire tracing. Sinus bradycardia at 110/min is likely due to the transplacental effects of digoxin and flecainide. (b) cardiac time intervals in both sinus rhythm and SVT with 1:1 VA conduction. Note that the QRS is wider during SVT, likely related to flecainide effect. (c) Aberrantly conducted PAC that initiates SVT. Note that T‐wave inversion is present. This could be due to digoxin. Dig, digoxin; fMCG, fetal magnetocardiogram; GA, gestational age; PAC, premature atrial contraction; SVT, supraventricular tachycardia.